Clinical trial NCT03422861 - References

Inflammatory Bowel Diseases — Nabilone Use For Acute Pain in Inflammatory Bowel Disease Patients

Citation(s)

•   Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL
  Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011 Dec;90(6):844-51. doi: 10.1038/clpt.2011.188. Epub 2011 Nov 2.
•   Alhouayek M, Muccioli GG
  The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med. 2012 Oct;18(10):615-25. doi: 10.1016/j.molmed.2012.07.009. Epub 2012 Aug 21.
•   Beaulieu P
  Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth. 2006 Aug;53(8):769-75. doi: 10.1007/BF03022793.
•   Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ
  Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain. 2003 Nov;106(1-2):169-72. doi: 10.1016/s0304-3959(03)00331-2.
•   Di Sabatino A, Battista N, Biancheri P, Rapino C, Rovedatti L, Astarita G, Vanoli A, Dainese E, Guerci M, Piomelli D, Pender SL, MacDonald TT, Maccarrone M, Corazza GR
  The endogenous cannabinoid system in the gut of patients with inflammatory bowel disea
•   Holdcroft A, Maze M, Dore C, Tebbs S, Thompson S
  A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology. 2006 May;104(5):1040-6. doi: 10.1097/00000
•   Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, Porreca F, Buckley NE, Makriyannis A, Malan TP Jr
  CB2 cannabinoid receptor mediation of antinociception. Pain. 2006 May;122(1-2):36-42. doi: 10.1016/j.pain.2005.12.018. Epub 2006 Mar 23.
•   Izzo AA, Sharkey KA
  Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010 Apr;126(1):21-38. doi: 10.1016/j.pharmthera.2009.12.005. Epub 2010 Feb 1.
•   Jain AK, Ryan JR, McMahon FG, Smith G
  Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol. 1981 Aug-Sep;21(S1):320S-326S. doi: 10.1002/j.1552-4604.1981.tb02610.x.
•   Kelly S, Jhaveri MD, Sagar DR, Kendall DA, Chapman V
  Activation of peripheral cannabinoid CB1 receptors inhibits mechanically evoked responses of spinal neurons in noninflamed rats and rats with hindpaw inflammation. Eur J Neurosci. 2003 Oct;18(8):2239-4
•   Lahat A, Lang A, Ben-Horin S
  Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion. 2012;85(1):1-8. doi: 10.1159/000332079. Epub 2011 Nov 17.
•   Lal S, Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, Steinhart H
  Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011 Oct;23(10):891-6. doi: 10.1097/MEG.0b013e328349bb4c.
•   Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM
  Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013 Oct;11(10):1276-1280.
•   Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM
  Treatment of Crohn's disease with cannabis: an observational study. Isr Med Assoc J. 2011 Aug;13(8):455-8. Erratum In: Isr Med Assoc J. 2011 Sep;13(9):582. Yablekovitz, Doron [corrected to Yablecovit
•   Salio C, Fischer J, Franzoni MF, Mackie K, Kaneko T, Conrath M
  CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport. 2001 Dec 4;12(17):3689-92. doi: 10.1097/00001756-200112040-00017.
•   Singh UP, Singh NP, Singh B, Price RL, Nagarkatti M, Nagarkatti PS
  Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol. 2012 Jan 15;258
•   Smith PA, Selley DE, Sim-Selley LJ, Welch SP
  Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol. 2007 Oct 1;571(2-3):129-37. doi: 10.1016/j.ejp
•   Toth C, Mawani S, Brady S, Chan C, Liu C, Mehina E, Garven A, Bestard J, Korngut L
  An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment
•   Turcotte D, Doupe M, Torabi M, Gomori A, Ethans K, Esfahani F, Galloway K, Namaka M
  Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. Pain Med. 2015 Jan;16(1):149-59. doi: 10.1111/pme.
•   Von Korff M, Saunders K, Thomas Ray G, Boudreau D, Campbell C, Merrill J, Sullivan MD, Rutter CM, Silverberg MJ, Banta-Green C, Weisner C
  De facto long-term opioid therapy for noncancer pain. Clin J Pain. 2008 Jul-Aug;24(6):521-7. doi: 10.1097/AJP.0b013e
•   Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J
  Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015 Jun 23-30;313(24):2456-7

Nabilone Use for Acute Pain in Inflammatory Bowel Disease Patients With Chronic Opioid Use Undergoing Gastrointestinal Surgery: A Single-centered Randomized Controlled Trial

Details for clinical trial NCT03422861